Imexpharm Corp (IMP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Imexpharm Corp (IMP) has a cash flow conversion efficiency ratio of 0.024x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₫55.75 Billion ≈ $2.12 Million USD) by net assets (₫2.34 Trillion ≈ $88.95 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see IMP market cap for the company's overall valuation and market capitalisation.
Imexpharm Corp - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Imexpharm Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Imexpharm Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Imexpharm Corp ranked by their cash flow conversion efficiency. Explore IMP cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Profound Medical Corp
TO:PRN
|
-0.222x |
|
GoldMining Inc
TO:GOLD
|
-0.027x |
|
AS Tallinna Vesi
F:A1T
|
0.049x |
|
Somboon Advance Technology Public Company Limited
BK:SAT
|
0.043x |
|
Shenzhen Weiye Decoration Group Co Ltd
SHE:300621
|
-1.074x |
|
Grupo Aeroméxico, S.A.B. de C.V.
NYSE:AERO
|
-0.312x |
|
Sagar Cements Limited
NSE:SAGCEM
|
0.048x |
|
Rhom Bho Property Public Company Limited
BK:TITLE
|
-0.254x |
Annual Cash Flow Conversion Efficiency for Imexpharm Corp (2019–2025)
The table below shows the annual cash flow conversion efficiency of Imexpharm Corp from 2019 to 2025. View IMP share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₫2.31 Trillion ≈ $87.63 Million |
₫54.17 Billion ≈ $2.06 Million |
0.023x | -76.29% |
| 2024-12-31 | ₫2.18 Trillion ≈ $82.95 Million |
₫216.27 Billion ≈ $8.22 Million |
0.099x | +610.25% |
| 2023-12-31 | ₫2.08 Trillion ≈ $79.20 Million |
₫-40.47 Billion ≈ $-1.54 Million |
-0.019x | -109.71% |
| 2022-12-31 | ₫1.89 Trillion ≈ $71.98 Million |
₫378.60 Billion ≈ $14.38 Million |
0.200x | +52.68% |
| 2021-12-31 | ₫1.79 Trillion ≈ $68.18 Million |
₫234.88 Billion ≈ $8.92 Million |
0.131x | +209.64% |
| 2020-12-31 | ₫1.73 Trillion ≈ $65.75 Million |
₫73.15 Billion ≈ $2.78 Million |
0.042x | -1.04% |
| 2019-12-31 | ₫1.56 Trillion ≈ $59.23 Million |
₫66.59 Billion ≈ $2.53 Million |
0.043x | -- |
About Imexpharm Corp
Imexpharm Corporation operates as a pharmaceutical company in Vietnam. The company's products include injectable antibiotics, oral antibiotics, cardiovascular, ophthalmology, musculoskeletal system, analgesic - anti-inflammatory - antipyretics, respiratory system, antihistamines and anti-allergy, central nervous system, digestive system, diabetes, anti-parasitic, external drugs, vitamins and mine… Read more